A review of our history

PlantResponse™ was founded in March 2008 as a Universidad Politécnica de Madrid (UPM) spin-off. Since then we have focused on developing highly innovative products by taking advantage of the know-how and techniques we have acquired through our experience in the agricultural domain.

Today, PlantResponse has a world-wide exclusive license to the initial technologies we developed, which enables us to identify and develop solutions to different types of botanical stress and help plant growth on a global scale.

PlantResponse is a company with world-class potential, a leader in the large and growing agricultural biotech market. Thanks to our expertise, our innovative technology and our constant pursuit of scientific excellence, PlantResponse is in the vanguard of discovering and developing innovative solutions for crop management.

Discover more about us!

Most Innovative Business Idea Award in ActúaUPM contest – Nov. 2007

<strong>Most Innovative Business Idea Award in ActúaUPM contest</strong> – Nov. 2007

In 2007, our co-founders Dr. Antonio Molina Fernández and Dr. Pablo Rodríguez Palenzuela, professors at Universidad Politécnica de Madrid (UPM), presented a new business idea in the ActúaUPM contest for innovative ideas. The project was awarded second place, and this event was the first step toward the creation of PlantResponse.

PRB Foundation – Feb. 2008

<strong>PRB Foundation</strong> – Feb. 2008

PlantResponse was founded in early 2008 by Dr. Antonio Molina Fernández and Dr. Pablo Rodríguez Palenzuela, by researchers from the Plant Biotechnology and Genomics Centre (CBGP) and by F&F Capital Funds. Their shared goal was to create synergy and value in their crop management research programs and thus meet challenging agricultural needs.

PRB1 Field Trials – May. 2008

<strong>PRB1 Field Trials</strong> – May. 2008

From 2008 to 2011, Dr. Antonio Molina focused his research on molecules derived from chitin. Trials on pepper and garlic were carried out in Murcia and Cuenca (Spain), and good results led to the development of our first commercial product: PRB1TM.

NEOTEC II Project CDTI – July 2011

<strong>NEOTEC II Project CDTI</strong> – July 2011

In 2011, PlantResponse obtained institutional funds from Neotec II Project, an initiative of the Centre for Industrial Technological Development (CDTI), designed to help start-up companies. This secured our early financial needs to start developing our products, technology and activities.

New strategic investor – Nov. 2011

<strong>New strategic investor</strong> – Nov. 2011

At the end of 2011, PlantResponse raised new capital with the incorporation of Camposeven, a strategic partner with over 40 years’ agricultural experience. Camposeven investment increased our capabilities to perform field trials and allowed us to get first-hand knowledge about the market and growers’ needs.

FAST-TRACK Laboratory Platform – July 2012

<strong>FAST-TRACK Laboratory Platform</strong> – July 2012

Our objective was to design a laboratory platform to screen discoveries in a fast and efficient way. This platform allows PlantResponse to perform multiple laboratory tests to validate new candidates.

FAST-TRACK Greenhouse Platform – Aug. 2013

<strong>FAST-TRACK Greenhouse Platform</strong> – Aug. 2013

PlantResponse sets up its greenhouse platform. A new facility was built in Murcia to allow PlantResponse to conduct field and greenhouse trials for tomato, corn, barley, and cabbages.

PRB1 commercialized as Stemicol® – Nov. 2013

<strong>PRB1 commercialized as Stemicol<sup>®</sup></strong> – Nov. 2013

After two years of good results in field trials, PlantResponse and Lida Plant Research signed a licensing agreement to develop and promote our product PRB1TM under the commercial name of Stemicol®. Nowadays, Stemicol is marketed by Lida Plant Research in Europe and South America.

US patent granted – July 2015

<strong>US patent granted</strong> – July 2015

On July, 2015 PlantResponse obtained its first patent in the USA. We believe the protection of intellectual property (IP) is essential to rewarding innovation and promoting our technological advances.

Capital raise in Series A round – Aug. 2015

<strong>Capital raise in Series A round</strong> – Aug. 2015

After achieving its objectives and milestones in technology and product development, PlantResponse raised €5.7 million in Series A funding. Monsanto Growth Ventures, Middleland Capital, Caixa Capital Risc and Novozymes participated in the round. This investment expands our capacities in R&D and will enable the continued growth of our technology platform.

Worldwide trials – Dec. 2015

<strong>Worldwide trials</strong> – Dec. 2015

With new partnerships and product development status, PlantResponse launched multiple crop trials in more than 20 countries around the world.

Most Innovative Biotech SME – Sep. 2016

<strong>Most Innovative Biotech SME</strong> – Sep. 2016

At the 2016 EuropaBio Awards, PlantResponse was proclaimed the Most Innovative European Biotech SME in the agricultural category.

New corporate identity – Sep. 2017

<strong>New corporate identity</strong> – Sep. 2017

PlantResponse renews its corporate image to reinforce its position as a global company specialized in plant science and its commitment to being scientists for farmers.

Opening of North American Headquarters – Oct. 2017

<strong>Opening of North American Headquarters</strong> – Oct. 2017

Following our global growth strategy, PlantResponse opened the new North American headquarters in North Carolina’s Research Triangle Park, a key location for the North American market.

Cybelion® approved for organic agriculture – Oct. 2018

<strong>Cybelion<sup>®</sup> approved for organic agriculture</strong> – Oct. 2018

PlantResponse receives organic certification for its innovative biostimulant Cybelion®, following a meticulous evaluation in accordance with the European Regulation (EC) No. 834/2007 on organic production.

Series B First-Round Funding Close – Dec. 2018

<strong>Series B First-Round Funding Close</strong> – Dec. 2018

PlantResponse raised $6.9 million on the first round of the Series B investment. Yara Germinate and iSelect Fund joined existing investors Bayer Ventures (formerly Monsanto Growth Ventures), Middleland Capital, and Novozymes in this round.